. 2020 Feb 10;20:105. doi: 10.1186/s12885-020-6572-6

Table 2.

Intervention details

Author	Malignancies	PIPAC Chemo	Systemic Chemo	Interval between PIPAC
Alyami et al. [27]	Gastric, Colon, Ovarian, Mesothelioma, Pseudomyxoma and others	Oxa, C/D or mito-c	NR	NR
Demtröder et al. [28]	Colorectal	Oxa	NR	6 weeks^a
Falkenstein et al. [29]	Biliary tract	C/D	NR	6 weeks^a
Graversen et al. [30]	Pancreatic	C/D	Gem + S-1	4–6 weeks^a
Hilal et al. [31]	Gynecological	C/D	NR	4–6 weeks^a
Khomyakov et al. [24]	Gastric	C/D	XELOX	6 weeks^a
Khosrawipour et al. [32]	Pancreatic	C/D	Gem+nab-Pax Folfirinox Gem	6 weeks^a
Nadiradze et al. [33]	Gastric	C/D	NR	6 weeks^a
Reymond et al. [34]^a	CUP, Pancreatic and Gallbladder	C/D	Cis + Gem	6 weeks^a
Robella et al. [26]	Mesothelioma, Ovarian, Colorectal, Pseudomyxoma and Gastric	C/D or Oxa	Topotecan Folfox+cetuximab Folfoxiri Paclitaxel Folfiri Paclitaxel+Ramcirumab Xelox Paclitaxel Pemetrexed	6 weeks^a
Farinha et al. [35]	Gynecological, Colorectal, Gastric, Small bowel, Appendix, Pseudomyxoma and Mesothelioma	NR	NR	6 weeks^a
Hübner et al. [36]	Gynecological and Digestive	C/D or OXA	NR	6 weeks^a

C/D Cisplatin/Doxorubicin, CUP cancer of unknown primary, gem Gemcitabine, mito-c Mitomycin c, nab-pax nab-Paclitaxel, NR not reported, Oxa Oxaliplatin,

^a Pursued rather than actual interval